Remohab
Funding Series
Series A
Funding Amount
¥200m
[data from INITIAL 2024 Dec]
Healthcare/Medtech Manufacturing

About

As the first company established through the Japan Biodesign Program, Remohab has developed an online-managed remote cardiac rehabilitation system. Its acquisition by the Air Water Group represents Japan’s first M&A exit in the digital therapeutics (DTx) sector.

Milestone

In 2024, Remohab completed Japan's first physician-initiated Phase III clinical trial of a remote cardiac rehabilitation system. On June 23, 2025, the company's Remohab CR U system received regulatory approval in Japan. With an eye toward future international expansion, Remohab aims to first launch the product in Japan and promote its adoption nationwide.
Visit Site
We're Here to Help
Have questions? Not sure where to start? Send us an email and let’s chat!
Email Us
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.